CORCEPT THERAPEUTICS INC
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
CORT$72.77+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 6. EXHIBITS
| ExhibitNumber | Description of Document |
| 3.1 | Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on May 24, 2023). |
| 3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on December 11, 2023). |
| 10.1#^ | Consulting Services Agreement, dated as of September 22, 2026 and effective as of October 1, 2026, by and between Corcept Therapeutics Incorporated and Sean Maduck. |
| 10.2# | Employment Offer Letter to Roberto Vieira, dated October 16, 2023. |
| 10.3# | Severance and Change in Control Agreement by and between Corcept Therapeutics Incorporated and Roberto Vieira, dated January 29, 2024. |
| 10.4# | Employment Offer Letter to Justin Gunn, dated June 27, 2024. |
| 10.5# | Severance and Change in Control Agreement by and between Corcept Therapeutics Incorporated and Justin Gunn, dated October 1, 2026. |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant. |
| 31.2 | Rule 13a-14(a)/15d-14(a) Certifications of Atabak Mokari, Chief Financial Officer of the registrant. |
| 32.1 | 18 U.S.C. Section 1350 Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant. |
| 32.2 | 18 U.S.C. Section 1350 Certifications of Atabak Mokari, Chief Financial Officer of the registrant. |
| 101 | The following materials from the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2026 and December 31, 2025, (ii) Unaudited Condensed Consolidated Statements of Income for the three and nine month periods ended September 30, 2026 and 2025, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Income for the three and nine month periods ended September 30, 2026 and 2025, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine month periods ended September 30, 2026 and 2025, (v) Unaudited Condensed Consolidated Statements of Stockholders’ Equity and (vi) Notes to Unaudited Condensed Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
| # | Indicates a management contract or compensatory plan or arrangement. |
|---|---|
| ^ | Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.